{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lantus%C2%AE&page=2",
    "query": {
      "intervention": "Lantus®",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lantus%C2%AE&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T15:25:43.174Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02058160",
      "title": "Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Insulin glargine/lixisenatide (HOE901/AVE0010)",
          "type": "DRUG"
        },
        {
          "name": "Insulin glargine (HOE901)",
          "type": "DRUG"
        },
        {
          "name": "Metformin (Background Drug)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 736,
      "start_date": "2014-01",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2017-05-09",
      "last_synced_at": "2026-09-27T15:25:43.174Z",
      "location_count": 108,
      "location_summary": "Birmingham, Alabama • Sun City, Arizona • Tempe, Arizona + 91 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02058160"
    },
    {
      "nct_id": "NCT00612040",
      "title": "Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes",
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "insulin degludec",
          "type": "DRUG"
        },
        {
          "name": "insulin glargine",
          "type": "DRUG"
        },
        {
          "name": "insulin aspart",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 178,
      "start_date": "2008-01",
      "completion_date": "2008-06",
      "has_results": true,
      "last_update_posted_date": "2017-03-03",
      "last_synced_at": "2026-09-27T15:25:43.174Z",
      "location_count": 9,
      "location_summary": "Walnut Creek, California • Honolulu, Hawaii • Idaho Falls, Idaho + 5 more",
      "locations": [
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Idaho Falls",
          "state": "Idaho"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Hyattsville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00612040"
    },
    {
      "nct_id": "NCT04075513",
      "title": "Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Insulin glargine, 300 U/ml",
          "type": "DRUG"
        },
        {
          "name": "Insulin degludec, 100U/ml",
          "type": "DRUG"
        },
        {
          "name": "Background therapy: Rapid acting insulin analogs",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 343,
      "start_date": "2019-10-09",
      "completion_date": "2021-09-16",
      "has_results": true,
      "last_update_posted_date": "2022-11-14",
      "last_synced_at": "2026-09-27T15:25:43.174Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04075513"
    },
    {
      "nct_id": "NCT00670228",
      "title": "Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "AMI"
      ],
      "interventions": [
        {
          "name": "Insulin Glargine (LANTUS)",
          "type": "DRUG"
        },
        {
          "name": "Insulin Glulisine (Apidra)",
          "type": "DRUG"
        },
        {
          "name": "Standard Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "35 Years to 80 Years"
      },
      "enrollment_count": 34,
      "start_date": "2008-04",
      "completion_date": "2009-11",
      "has_results": true,
      "last_update_posted_date": "2011-02-11",
      "last_synced_at": "2026-09-27T15:25:43.174Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00670228"
    },
    {
      "nct_id": "NCT01226043",
      "title": "Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Insulin Glargine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 405,
      "start_date": "2010-10",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2013-08-12",
      "last_synced_at": "2026-09-27T15:25:43.174Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01226043"
    },
    {
      "nct_id": "NCT01240200",
      "title": "Satisfaction of Treatment Among Elderly Patients With Insulin Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Glargine",
          "type": "DRUG"
        },
        {
          "name": "glargine via insulin pen",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2011-01",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2018-10-31",
      "last_synced_at": "2026-09-27T15:25:43.174Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01240200"
    },
    {
      "nct_id": "NCT02666430",
      "title": "Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Mylan's insulin glargine",
          "type": "DRUG"
        },
        {
          "name": "Lantus®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mylan Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "66 Years",
        "sex": "ALL",
        "summary": "18 Years to 66 Years"
      },
      "enrollment_count": 127,
      "start_date": "2015-12",
      "completion_date": "2017-07",
      "has_results": true,
      "last_update_posted_date": "2022-03-03",
      "last_synced_at": "2026-09-27T15:25:43.174Z",
      "location_count": 39,
      "location_summary": "Fresno, California • Greenbrae, California • La Jolla, California + 36 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Tustin",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02666430"
    },
    {
      "nct_id": "NCT00574405",
      "title": "Preservation of Pancreatic Beta Cell Function Through Insulin Pump Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "MDI (split-mix NPH insulin + regular insulin or Lantus + Novolog® [or Humalog®])",
          "type": "DRUG"
        },
        {
          "name": "CSII (Animas Corporation insulin pump, model IR 1200)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Arkansas Children's Hospital Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "8 Years to 18 Years"
      },
      "enrollment_count": 24,
      "start_date": "2005-04",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2017-09-13",
      "last_synced_at": "2026-09-27T15:25:43.174Z",
      "location_count": 1,
      "location_summary": "Little Rock, Arkansas",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00574405"
    },
    {
      "nct_id": "NCT03668808",
      "title": "Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "Insulin Degludec",
          "type": "DRUG"
        },
        {
          "name": "Insulin Glargine",
          "type": "DRUG"
        },
        {
          "name": "TRESIBA® FLEXTOUCH®",
          "type": "DEVICE"
        },
        {
          "name": "LANTUS® SOLOSTAR® INSULIN PEN",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Sansum Diabetes Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 25,
      "start_date": "2018-11-16",
      "completion_date": "2020-09-19",
      "has_results": true,
      "last_update_posted_date": "2022-11-01",
      "last_synced_at": "2026-09-27T15:25:43.174Z",
      "location_count": 2,
      "location_summary": "Santa Barbara, California • Honolulu, Hawaii",
      "locations": [
        {
          "city": "Santa Barbara",
          "state": "California"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03668808"
    },
    {
      "nct_id": "NCT03170544",
      "title": "Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus",
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "MK-1092, 4.0 nmol/kg",
          "type": "DRUG"
        },
        {
          "name": "MK-1092, 8.0 nmol/kg",
          "type": "DRUG"
        },
        {
          "name": "MK-1092, 16 nmol/kg",
          "type": "DRUG"
        },
        {
          "name": "MK-1092, 32 nmol/kg",
          "type": "DRUG"
        },
        {
          "name": "MK-1092, 64 nmol/kg",
          "type": "DRUG"
        },
        {
          "name": "Glargine 3.0 nmol/kg",
          "type": "DRUG"
        },
        {
          "name": "Lispro 1.2 nmol/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo to glargine",
          "type": "DRUG"
        },
        {
          "name": "Placebo to MK-1092",
          "type": "DRUG"
        },
        {
          "name": "Dextrose",
          "type": "OTHER"
        },
        {
          "name": "Insulin",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 69,
      "start_date": "2017-08-16",
      "completion_date": "2018-11-08",
      "has_results": true,
      "last_update_posted_date": "2019-11-15",
      "last_synced_at": "2026-09-27T15:25:43.174Z",
      "location_count": 1,
      "location_summary": "Chula Vista, California",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03170544"
    }
  ]
}